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A B S T R A C T   
Effect biomarkers can be used to elucidate relationships between exposure to environmental chemicals and their 
mixtures with associated health outcomes, but they are often underused, as underlying biological mechanisms 
are not understood. We aim to provide an overview of available effect biomarkers for monitoring chemical 
exposures in the general and occupational populations, and highlight their potential in monitoring humans 
exposed to chemical mixtures. We also discuss the role of the adverse outcome pathway (AOP) framework and 
physiologically based kinetic and dynamic (PBK/D) modelling to strengthen the understanding of the biological 
mechanism of effect biomarkers, and in particular for use in regulatory risk assessments. An interdisciplinary 
network of experts from the European chapter of the International Society for Exposure Science (ISES Europe) 
and the Organization for Economic Co-operation and Development (OECD) Occupational Biomonitoring activity 
of Working Parties of Hazard and Exposure Assessment group worked together to map the conventional 
framework of biomarkers and provided recommendations for their systematic use. We summarized the key as-
pects of this work here, and discussed these in three parts. Part I, we inventory available effect biomarkers and 
promising new biomarkers for the general population based on the H2020 Human Biomonitoring for Europe 
(HBM4EU) initiative. Part II, we provide an overview AOP and PBK/D modelling use that improved the selection 
and interpretation of effect biomarkers. Part III, we describe the collected expertise from the OECD Occupational 
Biomonitoring subtask effect biomarkers in prioritizing relevant mode of actions (MoAs) and suitable effect 
biomarkers. Furthermore, we propose a tiered risk assessment approach for occupational biomonitoring. 
Several effect biomarkers, especially for use in occupational settings, are validated. They offer a direct 
assessment of the overall health risks associated with exposure to chemicals, chemical mixtures and their 
transformation products. Promising novel effect biomarkers are emerging for biomonitoring of the general 
population. Efforts are being dedicated to prioritizing molecular and biochemical effect biomarkers that can 
provide a causal link in exposure-health outcome associations. This mechanistic approach has great potential in 
improving human health risk assessment. New techniques such as in silico methods (e.g. QSAR, PBK/D model-
ling) as well as ‘omics data will aid this process. 
Our multidisciplinary review represents a starting point for enhancing the identification of effect biomarkers 
and their mechanistic pathways following the AOP framework. This may help in prioritizing the effect biomarker 
implementation as well as defining threshold limits for chemical mixtures in a more structured way. Several ex 
vivo biomarkers have been proposed to evaluate combined effects including genotoxicity and xeno-estrogenicity. 
There is a regulatory need to derive effect-based trigger values using the increasing mechanistic knowledge 
coming from the AOP framework to address adverse health effects due to exposure to chemical mixtures. Such a 
mechanistic strategy would reduce the fragmentation observed in different regulations. It could also stimulate a 
harmonized use of effect biomarkers in a more comparable way, in particular for risk assessments to chemical 
mixtures.   
1. Introduction 
Human biomonitoring (HBM) measures people’s exposures to toxic 
substances in the environment and is a growing area in environmental 
and occupational health (Choi et al. 2015). HBM uses biomarkers to 
assess specific exposures and predict the risk of (adverse) health effects 
in individuals and populations (Ladeira and Viegas 2016). Biomarkers 
are chemicals, their metabolites, or products of an interaction between a 
chemical and some target molecule that is measured in the human body 
(WHO 2006). They are indicators of changes, or events, in biological 
systems that result from complex pathways of human exposure and play 
an important role in elucidating dose–effect relationships. Biomarkers 
are generally divided into three main categories: exposure, effect, and 
susceptibility (WHO 1993, NRC 2006). While exposure biomarkers re-
veals the concentration of a parent compound or its metabolites in 
human biospecimens, effect biomarkers are measurable biochemical, 
physiological, and behavioral effects or other alterations within an or-
ganism that depending upon the magnitude, can be recognized as 
associated with an established or possible health impairment or disease 
(WHO 1993, NRC 2006). This definition is generally accepted in Europe 
and used in the H2020 European Human Biomonitoring Initiative 
(HBM4EU) project., HBM4EU is a joint effort of 30 countries, including 
the European Economic Area (EEA) and the European Commission 
involving European Food Safety Agency (EFSA) and European Chem-
icals Agency (ECHA) (HBM4EU et al., 2017). Effect biomarkers often 
reflect subclinical changes before the onset of disease. They may also 
suggest effects from exposures to chemical mixtures or aggregate 
exposure (i.e. exposure to the same chemical from multiple exposure 
routes) through different sources (Bopp et al. 2018, Santonen et al. 
2019). For example, an elevated frequency of micronuclei in human 
peripheral blood lymphocytes was predictive for cancer risk (Bonassi 
et al. 2007). In an occupational setting, the frequency of micronuclei 
correlated with exposures to hexavalent chromium (Annangi et al. 
2016). Effect biomarkers provide a link between internal exposure and 
preferably early health effects. Consequently, they range from early 
biological changes (e.g. enzyme induction responses) to altered struc-
ture and function (Ladeira and Viegas 2016). Effect biomarkers can help 
in identifying early effects in humans at low doses, establish dos-
e–response relationships, explore mechanisms and increase the biolog-
ical plausibility of epidemiological associations. In addition, effect 
biomarkers can improve the risk assessment of specific chemical families 
as well as exposure to chemical mixtures (HBM4EU et al., 2017). A 
chemical mixture is defined as an exposure to multiple chemicals via a 
single or multiple sources and exposure routes, that may or may not be 
identifiable and that may contribute to a joint toxicity in a target pop-
ulation (Bopp et al. 2018). Susceptibility biomarkers reflect intrinsic or 
acquired proneness of an organism to respond to specific chemical 
substances. Inter-individual biological differences may cause some in-
dividuals to be more susceptible to environmentally induced diseases 
(DeBord et al. 2015). For example, polymorphisms of relevant xenobi-
otic metabolizing enzymes (e.g. cytochrome P450 enzymes) are used as 
susceptibility biomarkers (Bi et al. 2016, Kim et al. 2016). 
The discovery of new effect biomarkers following exposures to single 
chemicals and chemical mixtures will increase the weight of evidence in 
exposure-health outcome associations in epidemiological studies as well 
as experimental exposure studies with human volunteers (Fernández 
et al. 2019a, 2019c). Although, several effect biomarkers have been 
introduced in a number of environmental health studies, only a few have 
been considered to be sufficiently validated. Moreover, effect bio-
markers have been used to a lesser extent than exposure biomarkers, 
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thus constituting an understudied field. The main challenge in HBM 
studies is to link effect biomarkers to specific exposures (i.e. sources, 
pathways and routes) and early health effects (i.e. the key events along 
the pathway from exposure to disease). Effect biomarkers represent 
physiological processes where upon many different chemical families 
affect pathways and organs similarly. Thus, chemicals targeting meta-
bolic disorders for instance could be mapped with a set of validated 
effect biomarkers covering the main metabolic pathways. One way to fill 
the current gap and determine the group of chemicals that can converge 
into a particular disease is to integrate mechanistic and toxicologic 
knowledge using new approaches that make best use of all available 
experimental and epidemiological knowledge such as adverse outcome 
pathway (AOP) framework and physiologically-based kinetic and dy-
namic (PBK/D) modelling. With the influx of new data, there is a need to 
create a framework to organize and use the chemical hazard, kinetics 
and exposure information to improve risk assessment processes. This is 
also consistent with the 21st century paradigm indicating the shift in 
human health risk assessment from identification of apical endpoints of 
toxicity to understanding the mechanisms of toxicity (Lanzoni et al. 
2019). To reflect this shift, we present here an updated conventional 
conceptual pathway representing the continuum between environ-
mental chemical exposures and clinical diseases (NRC 2006). Fig. 1 il-
lustrates this integrative conceptual framework identifying the major 
steps in the continuum from exposure to chemicals to a gradual 
disruption of biological functions (including early signals and already 
altered structure and function) until clinical onset of diseases. The key 
aspect supporting this framework is the implementation of a given effect 
biomarker for a given chemical family that must be based on toxico-
logical data showing that the chemical family under study is able to alter 
a particular physiological system and its related molecular and 
biochemical pathways. In other words, toxicological and AOP data 
determine the physiological validity of using a set of effect biomarkers 
for chemicals sharing the same Mode of Action (MoA) (Ankley et al. 
2010). AOPs are useful in supporting chemical risk assessment because 
they provide mechanistic reasoning supporting the association. 
Additionally, PBK/D models can support, by means of mathematical 
simulations, the interpretation of both exposure and effect biomarkers. 
One example of an integrative conceptual framework from exposure to 
the adverse outcome was recently published by (Mustieles et al. 2020). 
They demonstrated how a previously published AOP on estrous cycle 
disruption helped prioritize hormonal biomarkers and better interpret 
biomarker data. Furthermore, they also described how to merge 
different AOPs in the AOP wiki to create an AOP network for a novel 
biomarker of altered neurodevelopment (BDNF-brain-derived neuro-
trophic factor), and link this biomarker to chemical exposure. 
Among the diverse effect biomarkers available, some allow a direct 
interpretation in terms of risk at an individual level, such as blood 
pressure or hormone levels with validated reference values. Others 
provide information that can only be interpreted at the population level 
such as genotoxicity biomarkers or novel biomarkers for which refer-
ence levels are not available. In these cases, the data obtained is 
compared with the data from a population with a background exposure 
as a reference, which is typical for occupational studies, or with a 
matched non-exposed population in general population studies. At the 
group level, the data may aid in identifying groups at increased risk, but 
in this situation, individual data should be communicated to partici-
pants of the HBM study within the context of the group results. 
Conversely, data on effect biomarkers such as blood pressure or hor-
mone levels may be communicated individually to provide relevant 
inputs for health surveillance, in addition to risk assessment. 
A major challenge in effect biomarker discovery and validation for 
health outcome assessment, is the understanding of the complex bio-
logical mechanisms involved in disease pathogenesis. The use of effect 
biomarkers in regulatory risk assessment of chemicals could drive the 
research forward, and thus the evidence for strengthen an exposur-
e–health outcome relationship. It would also improve the interpretation 
of effect biomarker data, advance the field of effect biomarkers for the 
general population and workers, and identify validated and suitable 
effect biomarkers. 
Here, we aim to provide an overview of available effect biomarkers 
Fig. 1. Integrative conceptual framework from exposure to the adverse outcome, including the roles of exposure and effect biomarkers, Adverse Outcome Pathways 
(AOP), and physiologically based kinetic and dynamic (PBK/D) models. ADME: adsorption, distribution, metabolism, excretion. MIE: Molecular Initiating Event. KEs: 
Key Events. 
M. Zare Jeddi et al.                                                                                                                                                                                                                            
Environment International 146 (2021) 106257
4
Table 1 
Inventory of effect biomarkers reported in the literature in human biomonitoring and epidemiologic studies, related to exposure to specific chemicals (Mustieles et al. 
2018, Fernández et al. 2019a, 2019c).  
Type of Effect 
Biomarker 
Related health outcomes Effect Biomarker and other indicators Used for Chemicals Strengths/ Limitations 
Anthropometric 
biomarkers 
Obesity, metabolic and 
reproductive diseases 
Birth Weight, Birth Length and Head 
circumference, Body Mass Index (BMI), 




(PFOS), Perfluorooctanoic acid 
(PFOA); Acrylamide 
Easy to assess, reliable and 
predictive of cardio-metabolic 
outcomes. 
AGD constitute a marker of 




Cardiovascular events including 
ischemic heart disease, 
atherosclerosis and stroke 
Blood pressure (systolic, diastolic, and 
pulse pressure), 1st-, 2nd-and 3rd-min 
Heart Rate Recovery (HRR), carotid 
intima media thickness (cIMT), and 
electrocardiographic (ECG) parameters 
(QT interval, JT interval, PR interval, 
QRS duration, and QT dispersion) 
Bisphenols; Inorganic arsenic Specific of heart variables. 
However, with the exception of 
blood pressure, are not easy to 
implement in large HBM studies. 
Serum lipids Atherosclerosis and Metabolic 
Syndrome 
Low density lipoprotein (LDL), high 
density lipoprotein (HDL), total 
cholesterol (TC) and triglycerides (TG)], 
related to obesity and cardio-metabolic 
diseases; Adipokines [Leptin and 
Adiponectin]a, as biomarkers of adipose 
tissue function. 
Bisphenols; PAHs; PFOS, PFOA; 
Brominated Flame Retardants; 
Inorganic arsenic; Mycotoxins 
There are reference and cut-off 
values for these biomarkers. 
Although serum lipids may be 
useful in adult and elder 
populations, they may not be 
enough sensitive for children (with 
the exception of adipokines). 
Glucose homeostasis Type 2 diabetes mellitus Fasting blood glucose (FBG), fasting 
insulin levels and glycated hemoglobin 
(HbA1c) and the homeostatic model 
assessment (HOMA)b 
Bisphenols; Phtalates; Brominated 
Flame Retardants; 
Organophosphate flame 
retardants; Acrylamide; Inorganic 
arsenic 
The relationship between fasting 
glucose and insulin levels 
calculated through the HOMA 
index, constitutes a validated 
biomarker of β-pancreatic cell 
function and insulin resistance. 
Hepatic biomarkers Fatty liver disease, hepatic 
injury 
Liver enzymes including alanine 
transaminase (ALT) and aspartate 
transaminase (AST), alkaline 
phosphatase (ALP), gamma-glutamyl 
transferase (GGT), serum bilirubin, 
prothrombin time (PT), the 
international normalized ratio (INR), 
and albumin; Cyp17A1, Cyp19A1, 
Cyp1A1, Cyp2E1, Cyp2J2. 
Bisphenols; PFOS, PFOA; 
Brominated Flame Retardants; 
Mycotoxins 
Reference levels exist. These 
markers are not always specific for 
the liver, and other tissues can 
contribute to altered levels. May 
not be sufficiently sensitive 
biomarkers in young and healthy 
populations. 
Renal function Renal injury, including kidney 
tubular and glomerular damage 
Serum creatinine; high molecular 
weight proteins such as urinary β2- 
microglobulin (B2-MG), α1- 
microglobulin, retinol-binding protein, 
albumin, transferrin, IgG 
Brominated Flame Retardants; 
Cadmium 
Urinary biomarkers such as B2- 
MG, NAG and KIM-1 are validated 
markers of tubular damage, that 
can be complemented with other 
markers of glomerular damage 
such as urinary albumin. 
They are evaluated in urine, 
constituting the most easily 
accessible biospecimen. 
Urinary B2-MG; NAG (N-acetyl-beta- 
(D)-glucosaminidase activity); ALAD 
(delta-aminolevulinic acid 
dehydratase); albumin; KIM-1 (kidney 
injury molecule-1); NGAL (Neutrophil 





Metabolic syndrome, immune 
system and psychological stress 
Hypothalamic corticotrophin-releasing 
factor (CRF), corticosterone (CORT), 
decreased hippocampal 11-hydroxyste-
roid dehydrogenase Type 1 (11-HSD 1), 
subcellular glucocorticoid receptor 
(GR) 
Inorganic arsenic Exist reference levels. Repeated 
cortisol measurements in saliva is 
feasible. It is an understudied 




Depending on age: pregnancy 
outcomes, puberty, fertility, 
metabolic disease and 
neurodevelopment. 
Luteinizing hormone (LH), follicle 
stimulating hormone (FSH), Total 
testosterone (TT), estradiol (E2), sex 
hormone binding-globulin (SHBG) 




Reference levels exist. Ratios 
among related hormones provide 
information on enzymatic activity 
and on feedback loops. 
Diurnal and seasonal variations. 
Requires the consideration of sex 
and developmental period. 
Sperm quality Fertility problems Sperm quality parameters including 
counts, concentration, motility and 
morphology. 
Hexavalent chromium Semen constitutes a non-invasive 
sample that can provide both in situ 
exposure and effect data, specific 
to the male reproductive system. 
Thyroid homeostasis Depending on age: 
Neurodevelopment, adverse 
pregnancy outcomes and 
metabolic disease 
Thyroid stimulating hormone (TSH), 
triiodothyronine (T3), thyroxine (T4), 
anti-thyroperoxidase (TPO) antibodies. 
Bisphenols; Phtalates; PFOS, 
PFOA; Brominated Flame 
Retardants; Organophosphate 
flame retardants; Inorganic 
arsenic; UV-filters 
Reference levels exist. Even 
subclinical dysfunction of thyroid 
homeostasis during pregnancy 
may affect offspring 
neurodevelopment. 
Cancer biomarkers Carcinogenesis Plasma carcinoembryonic antigen: NSE 
(neuron specific enolase); SCC 
(squamous cell carcinoma antigen); 
Hexavalent chromium Although cancer biomarkers may 
provide useful information, the 
inherent complexity of tumors 
(continued on next page) 
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Table 1 (continued ) 
Type of Effect 
Biomarker 
Related health outcomes Effect Biomarker and other indicators Used for Chemicals Strengths/ Limitations 
CYFRA21-1 (cytokeratin fragment 
antigen 21–1); CA72-4 (cancer antigen 
72–4); AFP (α-fetoprotein); 3-nitrotyro-
sine; prostate-specific antigen; high 
sensitive C reactive protein, CC16 
(Clara cell secretory protein), SP-D 
(surfactant protein D), TNF-α (tumor 
necrosis factor-α); Plasma total 
homocysteine 
makes their prediction more 
difficult, and it is preferable to use 





Chromosomal aberrations, sister 
chromatid exchange, micronucleous 
test 
PAHs; Hexavalent chromium; 
Acrylamide; Mycotoxins 
Some of these biomarkers, such as 
the micronucleous test, have been 
prospectively linked to cancer. 
While frequently used in 
occupational settings, their 
feasibility in population studies 
should be further studied. 
Oxidative stress Many different outcomes 
including cancer, cardio- 
metabolic diseases and adverse 
pregnancy outcomes 
DNA damage: Urinary 8-hydroxy-2′
-deoxyguanosine (8-OHdG) 
Lipid peroxidation: 8-isoprostane 
Hexavalent chromium; Inorganic 
arsenic; PAHs; Bisphenols; 
Phthalates; PFOA; Acrylamide; 
UV-filters 
Normally assessed in urine, which 
is preferred over serum. They are 
predictive of diverse chronic 
diseases including metabolic 
syndrome, cardiovascular disease 
and cancer. As a limitation, it is not 
specific of a defined health 
outcome. 
Given that this type of biomarkers 
capture disruptions at different 
levels of biological organization, 
they have been shown useful in 
mediation analyses between 
exposure biomarkers and health 
endpoints.  
Antioxidant defense: Glutathione 
peroxidase (GPx), selenium, and 
glutathione (GSH) 
Cadmium; Acrylamide; Inorganic 
arsenic  
Epigenetics and gene 
expression 
biomarkers 
Depends on window of exposure 
and the molecular targets 
investigated (from 
neurodevelopment, growth, 
metabolism and reproduction to 
cancer). 
Gene expression and methylation: p- 
MAPK expression, DNA methylation 
levels and histone methylation levels in 
oocytes 
Acrylamide DNA methylation is more stable 
over time compared to gene 
expression or circulating protein 
levels, which are subjected to 
short-term variations. 
DNA methylation regions must be 
carefully selected, mainly the 
promoter regions, so the status of 
DNA methylation is related to its 
gene expression. 
As a limitation, the predictive 
potential of epigenetic biomarkers 
for a given disease is unknown. 
Notwithstanding, recent findings 
are supporting their suitability.  
Arsenic methylation capacity; serum 
BDNF, serotonin receptor 5B gene 
expression; Protein expression PSD-95, 
SYP; miRNA-219, CaMKII; H3K18ac, 
H3K9me2, H3K36me3; GR mRNA, H- 
Ras protein, Raf-1 protein, ERK 
expression; DNA methylation/ 
demethylation (5-methylcytosine, 5- 
hydroxymethylcytosine, DNA- 
methyltransferases, ten-eleven 
translocations genes); Methylated 
arginines, dimethyl arginine; 7-nAchR 
expression 




to infections, allergy, asthma, 
autoimmune diseases 
IgE; Protein complement (C3, 3a, 4), 
TNFα; Cytokine production; LTB4 
(leukotriene B4); Lymphocyte subsets 
characterisation 
Phthalates; PFOS, PFOA; 
Brominated Flame Retardants; 
Hexavalent chromium; Inorganic 
arsenic 
As an advantage, immune cells can 
be isolated from blood and studied 
in vitro or at a molecular level. 
Additional research is needed to 
further explore the most sensitive 
immune biomarkers in relation to 
environmental chemicals. 
Inflammation biomarkers: chemokines, 





Behavioral function (anxiety, 
depression, attention deficit and 
hyperactivity, etc.) 
Cognitive functioning 
(Intelligence quotient, working 
memory, vocabulary, etc.). 
CBCL: Child Behavior Check-List (6–18 
years); SDQ: Strengths and Difficulties 
Questionnaire; BASC-2: Behavior 
Assessment System for Children ; BASC- 
2: Behavior Assessment System for 
Children; BRIEF-P: Behavior Rating 
Bisphenols; Organophosphate 
flame retardants; Hexavalent 
chromium; Lead 
Molecular and biochemical 
markers of brain function are 
especially important, given that 
children are evaluated using 
psychological tests, in most cases 
completed by fathers or teachers. 
(continued on next page) 
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that can be used to monitorchemical exposures in the general and 
occupational populations and highlight their potential in monitoring 
populations exposed to chemical mixtures. We also discuss the role of 
the AOP framework and PBK/D modelling to strengthen the under-
standing of the biological mechanism of effect biomarkers, and in 
particular promote regulatory acceptance of effect biomarkers in risk 
assessment frameworks. We summarized the key aspects and discussed 
these in three parts. 
Part I, we inventory available effect biomarkers and promising new 
biomarkers for the general population based on the H2020 Human 
Biomonitoring for Europe (HBM4EU) initiative. 
Part II, we provide an overview AOP framework and PBK/D 
modelling use that improved the selection and interpretation of effect 
biomarkers. 
Part III, we describe the collected expertise from the OECD Occu-
pational Biomonitoring subtask effect biomarkers in prioritizing rele-
vant MoAs and suitable effect biomarkers. As a starting point, we 
propose to use existing AOP knowledge for derivation of cross- 
regulatory usable effect-based trigger values to address known and un-
known mixtures encountered in the occupational setting. MoA specific 
exposure biomarkers should be used in setting preliminary health-based 
threshold values. We provide a prioritization of suitable effect bio-
markers for regulatory use from the perspective of the European Chapter 
of the International Society for Exposure Science (ISES Europe) and 
OECD Occupational Biomonitoring working groups. 
The combination of suitable effect biomarker with future effect- 
based trigger values will lead to an improved and systematical use of 
effect biomarker, which in turn will reduce chemical exposures and 
related health effects in human populations. 
2. Methods 
This is a joint effort of the ISES Europe network and OECD Occu-
pational Biomonitoring activity of Working Parties of Hazard (WPHA) 
and Exposure Assessment (WPEA) groups. These working groups con-
stitutes of an interdisciplinary network of experts in different regulatory 
and research roles. In addition, some of the experts are already 
contributing to HBM4EU projects, as well as in other national HBM 
programs. The main aim for these working groups is to promote the use 
of effect biomarkers in regulatory risk assessment frameworks for 
chemical and chemical mixtures to strengthen decision-making 
processes. 
The present work follows the updated framework (Fig. 1), with a 
separate focus for the general population and the occupational popula-
tion. Effect biomarker profiles differ by exposure ranges (Mustieles et al. 
2020), and consequently, will differ between the general population 
Table 1 (continued ) 
Type of Effect 
Biomarker 
Related health outcomes Effect Biomarker and other indicators Used for Chemicals Strengths/ Limitations 
Psychiatric and 
neurodegenerative diseases 
Inventory of Executive Function- 
Preschool; WISC: Wechsler Intelligence 
Scale for Children; Social Behavior 
(Skills Improvement Rating scale) 
WISC-IV; Standard Progressive matrices 
testc 
Neurotrophins like BDNF 
constitute promising effect 
biomarkers of brain function 
currently investigated in different 
fields and HBM4EU project. BDNF 
counts with the support of a 
recently developed AOP network ( 
Mustieles et al., 2020) 
Hypothalamic-Pituitary-Adrenal (HPA) 
axis [Corticotropin releasing hormone 
(CRH) – Adrenocorticotropin hormone 
(ACTH) – Cortisol] 
Brominated Flame Retardants; 




Behavioral function (anxiety, 
depression, attention deficit and 
hyperactivity, etc.) 
Cognitive functioning 
(Intelligence quotient, working 
memory, vocabulary, etc.). 
Psychiatric and 
neurodegenerative diseases 
Depends on window of exposure 
and the molecular targets 
investigated (from 
neurodevelopment, growth, 
metabolism and reproduction to 
cancer). 
Serum brain derived neurotrophic 
factor (BDNF); blood BDNF DNA 
methylation 
Bisphenols; Lead; PFOS, PFOA 
Molecular and biochemical markers of 
brain function are especially important, 
given that children are evaluated using 
psychological tests, in most cases 
completed by fathers or teachers. 
Neurotrophins like BDNF constitute 
promising effect biomarkers of brain 
function currently investigated in 
different fields and HBM4EU project. 
BDNF counts with the support of a 
recently developed AOP network ( 
Mustieles et al., 2020) 
Signaling biomarkers can shed light on 
potential MoAs. As a limitation, their 
predictive potential for a given disease 
is unknown. 
Ideally, signaling biomarkers should be 
complemented with more predictive 
biochemical biomarkers to better 
investigate a given adverse outcome. 
Cholinesterase activity Inorganic arsenic; Pesticides 




Corticosterone receptor (CR) 
Inorganic arsenic   
ESR1, ESR2, Faz, 
NR3C1 
Brominated Flame Retardants   
Rac1, Cdc42 expression; NGF, GAP-43 
mRNA; NR2A, PSD-95, p-CaMKII, 
SynGAP, p-ERK1/2 activity; mRNA 
tight junction (TJ) proteins, PI3K-Akt- 
mTOR signaling pathway 
Inorganic arsenic   
a Note that for the scientific substantiation of health claims on foods, a number of outcome variables allow for claims on cardiovascular health to be made such as 
beneficial changes in the blood lipid profile, arterial blood pressure, elastic properties of the arteries, endothelial function, plasma homocysteine concentrations, 
platelet aggregation and venous blood flow. 
b Note that for the scientific substantiation of health claims on foods, biomarkers in relation to blood glucose and related biomarkers have been described in EFSA 
guidelines. 
c Although neuropsychological tests could fit the effect biomarker definition, they are normally used as surrogate endpoint of brain function, that is, treated as a 
health outcome. The complementation of tests with measurable molecular/biochemical biomarkers of brain function is recommended. 
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(low exposures expected) and workers (high exposures expected). 
Therefore, while recognizing the overlaps in the general concept, we 
addressed the use of effect biomarkers in risk assessment for the general 
population separately from the occupational population. 
In part I, we summarized the most important existing effect bio-
markers used in epidemiologic studies based on preliminary (not 
curated) data collected and reported in the HBM4EU project for the 
general population (Mustieles et al. 2018, Fernández et al. 2019a, 
2019c). Under the HBM4EU project a series of comprehensive structured 
literature searches were performed to determine the most relevant effect 
biomarkers, as well as the chemical families more frequently associated 
with these biomarkers (HBM4EU et al., 2017). We presented our sum-
mary as an inventory of effect biomarkers previously reported in the 
literature for different chemical families. We emphasized the effect 
biomarkers’ advantages and limitations and discussed current progress 
and challenges in the utility of effect biomarkers as a useful HBM 
screening tool as well as their use for chemical mixtures in the general 
population. Each type of effect biomarker represents a different physi-
ological system, evaluation and discussion, and a comprehensive dis-
cussion for each chemical family is outside the scope of this work. 
Indeed, detailed discussions on available effect biomarkers are under 
evaluation in the HBM4EU project and a follow-up survey in the OECD 
Occupational Biomonitoring activity. 
In Part II, we discuss the incorporation of AOP and PBK/D modeling 
into effect biomarker frameworks addressing the complexity of effect 
biomarker utility. 
In Part III, we provide a prioritization of relevant MoAs and a 
recommendation of effect biomarkers in the occupational settings. We 
discuss general needs and recommendations collected from the OECD 
Occupational Biomonitoring activity of WPHA and WPEA within its 
subtask “effect biomarkers”. Subsequently, we suggest new paradigms 
and measurement strategies for 21st century HBM providing examples 
to improve chemical risk assessment. We summarize future work focus 
such as developing regulatory accepted effect-based trigger values, 
prioritizing MoAs in different regulations, characterizing suitable effect 
biomarkers and developing assessment schemes and tiered approaches. 
3. Results and discussion 
3.1. Part I. Available effect biomarkers for the general population 
An overview of available effect biomarkers is given in Table 1. These 
effect biomarkers were collected in the HBM4EU project, which aims to 
identify validated biomarkers reflecting specific exposures in different 
matrices and quantitatively linking exposures and adverse outcomes in 
human population studies (Fernández et al. 2019a, 2019c). We have 
added in Supplementary Material (Table S1) a summary of the HBM4EU 
project work on identifying potential effect biomarkers in human bio-
monitoring studies published in the scientific literature and their pro-
posed types of effect biomarkers for specific chemicals (Mustieles et al., 
2018, Fernández et al., 2019b). In our current work, we aim to provide 
an integrative overview, and do not discuss details of specific effect 
biomarkers but briefly mention some general limitations and advantages 
of the effect biomarkers listed in the Table 1. We provide in supple-
mentary information a checklist for effect biomarkers (Baken et al. 2019, 
Mustieles et al. 2020). 
HBM4EU developed relevant criteria for prioritizing effect bio-
markers and considered the following chemicals: Bisphenols, Phtha-
lates, Polycyclic Aromatic Hydrocarbons (PAHs), Perfluorinated 
Compounds (PFOS, PFOA), Brominated Flame Retardants, Organo-
phosphate retardants, Metals (Cadmium, Lead, Mercury, hexavalent 
Chromium), inorganic Arsenic, Acrylamide, Pesticides, Mycotoxins and 
UV-filters (Table 1) (Mustieles et al. 2018, Fernández et al. 2019a, 
2019c). Two scientific literature reviews; BPA and phthalates, con-
ducted in the HBM4EU project have recently been published (Mustieles 
et al., 2020; Baken et al., 2019). Specific reviews for other chemical 
families in relation to effect biomarkers are currently under preparation 
in the HBM4EU project. In addition, the HBM4EU project assessed 
different ex vivo bioassays for their potential use as effect biomarkers for 
addressing exposures to chemical mixtures (Rodríguez-Carrillo et al., 
Submitted). The conclusion was that chemical mixtures can be extracted 
and identified from human samples and their biological activity quan-
tified using different cell-based tools (Fernández et al. 2019a, 2019c). 
Some of the effect biomarkers have been validated (e.g. HOMA-IR, 
Kidney Injury Molecule-1 (KIM-1), micronucleus test, endogenous hor-
mones) including some that are predictive of specific health outcomes. 
Of note, KIM-1 is not only validated, but also qualified by the FDA 
biomarker qualification program1. Others constitute promising candi-
dates under active study such as BDNF in the case of neurodevelopment, 
and epigenetic omics biomarkers. Effect biomarkers are usually not 
specific to environmental chemicals. Thus, the selection of the best effect 
biomarkers to map the potential impact of specific chemical families on 
human health should be based on toxicological knowledge (Mustieles 
et al. 2020). While some of the effect biomarkers are validated and/or 
qualified scientifically, none of the mentioned effect biomarkers are 
currently used in the regulatory risk assessment of the general popula-
tion. While few effect biomarkers (e.g. cholinesterase inhibition) are 
currently used in regulatory occupational biomonitoring. We aim to 
pave the way for more systematic use and regulatory acceptance of ef-
fect biomarkers in risk assessment of chemicals. 
In general population studies, effect biomarkers can help in making 
regulatory decisions by increasing the weight of evidence for a given 
chemical family such as providing information on potential MoAs, 
assessing dose–response relationships, detection of subclinical effects, 
and evaluation of potential mediators between exposure biomarkers and 
health outcomes (Ferguson et al. 2017, Louro et al. 2019, Mustieles and 
Arrebola 2020). Overall, mechanistically-based effect biomarkers 
improve the understanding of correlative and causal relationships in 
observational and HBM studies. 
Biomarkers in the area of food and nutrition have been validated by 
EFSA to substantiate health claims (EU Regulation 1924/2006) such as 
“beneficial to human health” (EU. European Parliament 2006), and six 
guidance documents identifying these biomarkers have been published. 
These biomarkers are related to functions of the nervous system 
including psychological functions (EFSA Panel on Dietetic Products, 
2012a, 2012b, 2012c), muscle function and physical performance (EFSA 
Panel on Nutrition, Allergens et al. 2018), bone, joints, skin and oral 
health (EFSA Panel on Dietetic Products, 2012a, 2012b, 2012c), appetite 
ratings, weight management, and blood glucose concentrations (EFSA 
Panel on Dietetic Products, 2012a, 2012b, 2012c), the immune system, 
the gastrointestinal tract and defense against pathogenic microorgan-
isms (EFSA Panel on Dietetic Products and Allergies 2016), and anti-
oxidants, oxidative damage and cardiovascular health (EFSA Panel on 
Nutrition, Allergens et al. 2018). 
Accompanied by the challenges arising from the terminological and 
epistemological complexity of biomarker science, there are also prac-
tical challenges in generating, tracking, and aggregating the evidence 
for a biomarker used in the general population studies. Several of these 
challenges are discussed in the following sections. 
3.1.1. Technical Feasibility: The pre-analytical and analytical factors 
The feasibility of an effect biomarker will rely on the possibility of 
measuring it in an accessible biological matrix (e.g., blood, urine, or 
exfoliated cells), analytical cost for a large number of individuals, and 
technical viability. Technical issues associated with the development 
and pre-analytical validation of effect biomarkers are among others the 
lack of standardization of biological media (e.g. the selection of blood 
fraction, i.e. whole blood, plasma, or serum), analytical method, and 
1 https://www.fda.gov/drugs/cder-biomarker-qualification-program/list-q 
ualified-biomarkers 
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storage of samples. Furthermore, study design and execution may 
introduce bias and contribute to quantification errors in both laboratory 
and human studies. Altogether, key elements that are needed to move an 
effect biomarker from promising to successful in exposure assessment 
and health surveillance studies encompass appropriate study designs 
with ethical considerations, standardized and validated analytical 
methods along with sophisticated statistical analyses for interpreting 
results. 
It is important to indicate whether the existing analytical methods 
are sufficiently robust and sensitive (e.g. by geometric mean and stan-
dard deviations) to characterize (a) background levels in the population, 
and (b) levels at which biological effects occur. Meanwhile, an available 
analytical method might be sensitive in the laboratory but not in sam-
ples from human populations. For instance, micronuclei frequency is 
more sensitive in the laboratory than in the general population studies 
(Hayashi 2016). Therefore, effect biomarkers validated in in vitro 
methods must be tested in populations as part of a proof of concept. 
To address biological complexity and discover new effect bio-
markers, omics technologies have great potential as omics profiling 
enable a comprehensive characterization of a biological sample within a 
single analysis (Quezada et al. 2017). It has the advantage of being 
applicable for a large number of individuals and generating new bio-
markers for hazard identification and risk assessment. For instance, 
high-throughput transcriptomic (HTTr) can be used as a bottom up 
approach to identify chemical-induced changes (gene expression bio-
markers). These include oestrogen receptor α (ERα) and androgen re-
ceptor (AR) biomarkers for endocrine disrupting chemicals (EDCs). ERα 
and AR accurately identify both agonists (94–97%) and antagonists 
(93–98%) in microarray data derived from human breast or prostate 
cancer cell lines (Corton et al. 2019). The rise of genomics owing to the 
sequencing of the human genome has been closely followed by analo-
gous technologies that can be used to characterize downstream biolog-
ical events such as RNA expression (transcriptomics), proteins 
(proteomics) and metabolites (metabolomics) in cells, tissues or body 
fluids (Wild 2012). Epigenetic signatures are potential candidates to link 
exposure to phenotype alterations. Epigenetic biomarkers can incorpo-
rate information on environmental and lifestyle effects on health and 
disease, and monitor the effect from applied therapies (García-Giménez 
et al., 2017; Jeremias et al., 2020). Epigenetic studies provide infor-
mation on modifications of gene expressions rather than alteration in the 
underlying DNA sequence itself. They characterize the methylome- and 
microRNA profiles, and chromatin regulation such as nucleosome oc-
cupancy, DNA accessibility, transcription factor binding, and post- 
translational histone modifications (Wild, 2012; Jeremias et al., 
2020). Epigenetic biomarkers can be useful to predict and inform on 
health-related outcomes in later life from a specific early life exposure, 
but epigenetic endpoints are currently not yet incorporated into risk 
assessments. 
The metabolomics is the youngest of the omics technologies and still 
suffer from technological (e.g., sensitivity) and methodological (e.g., 
annotation) issues but hold great promises since it allows to profile, 
during the same analyses, endogenous (effect biomarkers) and exoge-
nous (exposure biomarkers) molecules In addition, the advent of high- 
throughput screening (HTS) with reporter gene assays and in silico mo-
dels that allow the rapid evaluation of hundreds to thousands of com-
pounds has been instrumental for the shift toward in vitro methods in 
toxicity testing and risk assessment (Escher et al. 2019). Reporter gene 
assays which are mechanism of action related, less variable, accurate, 
precise, and labor-saving are becoming more and more recognized and 
adopted in the quality control (Wang et al. 2020). The reporter gene 
assays are useful for identifying endocrine disruptors from the multitude 
of chemicals commonly in use (Kojima et al. 2004). 
In silico models can also offer opportunities using the chemical 
structure to simulate the exposure level and the (adverse) effects elicited 
by a chemical substance (Benfenati 2016). Regarding the possible use of 
in silico tools for the adverse effects, there are a variety of models 
available providing predicted values for properties such as binding to 
thyroid, estrogenic, androgen receptors, or property values closer to the 
apical effect, such as carcinogenicity, reproduction toxicity, and devel-
opmental toxicity (see Appendix A) (Judson et al. 2018). 
The emphasis is now to align various exposure platforms (e.g., in 
vitro, in vivo, and epidemiological) to support quantitative dos-
e–response relationship knowledge regarding chemicals and chemical 
mixtures. 
3.1.2. Validation of effect biomarkers 
To establish the credibility and effectiveness of an effect biomarker, 
it must be validated both analytically and physiologically. Analytical 
validation should follow recommendations such as those described in 
the ISO 17025/2017 scheme (ISO/IEC 2017) or a similar system. Only 
by having adequate control over the analytical method, is it possible to 
produce reliable, retrievable and repeatable results. Only then can the 
results be compared to one another. It may seem obvious that when 
there is a drift in results over time this may have consequences for 
interpretation of data and for the validity of conclusions being drawn 
from the results obtained, such as the (apparent) absence (or presence) 
of effects. Accuracy and precision are also indispensable characteristics 
for the analytical methods. 
Other key aspects of validation include establishing detection limits 
for the effect biomarker and an acceptable coefficient of variation. 
Physiological validation should follow the scientific justification of the 
effect biomarker and its response to changes in exposure. Measuring a 
biomarker based only on analytical feasibility or just repeating previous 
work is not a prudent way forward. A hallmark example of this is the 
quantification of thiobarbituric acid reactive substances (TBARS) or 
malondialdehyde (MDA) as a biomarker of oxidative stress. The tech-
nical approach is easy, swift and cheap, but the biological/physiological 
validity is poor (Griffiths et al. 2002, EFSA Panel on Nutrition, Allergens 
et al. 2018). In food and nutrition/health claims, several effect bio-
markers were considered as not reliable in vivo such as biomarkers of 
lipid peroxidation (in addition to TBARS and MDA, also high-density 
lipoprotein (HDL)-associated paraoxonases, conjugated dienes, breath 
hydrocarbons, autoantibodies against low-density lipoprotein (LDL) 
particles and ex vivo LDL resistance to oxidation). It was noted that MDA 
concentrations in blood or tissue can only be used as supportive evi-
dence (i.e. in addition to measurements of F2-isoprostanes and/or in vivo 
LDL oxidation) if appropriate analytical methods are used (e.g. by 
chromatography, viz not by colorimetry) (EFSA Panel on Nutrition, 
Allergens et al. 2018). 
Another aspect of physiological validation is the (lesser known) 
concept of “kinetics of biomarkers” or “ADME” (absorption, distribu-
tion, metabolism and excretion). It is well-known that biomarkers of 
exposure are influenced by the pattern of uptake and excretion of the 
target substance (or its parent compound or metabolite). For biomarkers 
of exposure, a thorough knowledge of ADME characteristics is pivotal 
for identification of an appropriate sampling scheme. For instance, an 
exposure biomarker that has a very short half-life (plasma, blood) re-
quires precise sampling times, or can better be sampled through excre-
tion into the urine. An example of this is artificial sweeteners that can be 
correctly measured in 24-h urine samples (Logue et al. 2016, Logue et al. 
2017, Logue et al. 2020). Effect biomarkers show similar variation over 
time and may even require an adequate timeframe for revealing an ef-
fect. That is the case of mutation fixation that requires the doubling of 
cells before being expressed and may disappear if the damaged cells are 
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removed due to cell turnover. Likewise, it is recognized that blood 
cholesterol markers need several months in order to react to an inter-
vention, viz. measuring blood cholesterol values after a few days of 
intervention is useless. A review of the concept of kinetics of biomarkers 
is provided by Verhagen et al (Verhagen et al. 2004). 
Physiological validation also entails the assessment of whether the 
effect biomarker reflects changes at the individual or at the population 
level. If the latter case applies, the population subgroups (i.e., age, sex, 
and ethnicity) for which there are an evidence that the biomarker 
actually reflects effect changes have to be documented. 
In summary, the physiological validation of effect biomarkers re-
quires some key aspects to be considered such as the dose–response 
relationship and the time-response as well as the robustness and 
reproducibility. Ideally, in vitro experiments with varying exposure 
levels demonstrating the differential impact on the effect biomarker 
would be required. Examination of the timeframe of response of the 
biomarker would indicate suitable sampling times for the biological 
samples. An ideal effect biomarker should be feasible, accurate, precise 
and robust, i.e. give consistent results across a range of populations and 
ethnic groups. Sex and age specific values/cut-offs should be deter-
mined, if appropriate, and potential interactions with combined expo-
sures should be documented. 
3.1.3. Using effect biomarkers for tracking complex mixtures of chemicals 
Regulatory guidelines for risk assessment of chemical mixtures 
recommend MoA of the individual chemical to predict dose–response 
characteristics of the mixture (Borgert et al., 2004). However, exposure 
to chemical mixtures is rather challenging for risk assessment and con-
siders: (i) dose or concentration addition for similar MoA chemicals; (ii) 
response addition for dissimilar MoA chemicals; and (iii) interactions 
between chemicals in the mixture. The term interaction includes all 
forms of joint actions that deviate from either dose or response addition. 
In exposure scenarios, chemical mixtures are rarely composed of either 
only similar or only dissimilar MoA substances. Therefore, recent 
guidelines for assessment of chemical mixtures have emphasized the 
necessity to incorporate interaction concepts and methods to evaluate 
the possible influence of such interactions on the overall joint toxicity of 
chemical mixtures (Kienzler et al. 2014). 
The European Commission (EC) published a communication in 2012 
stating that there is a need to better understand human and environ-
mental exposures to mixtures. There is a lack of a systematic, compre-
hensive and integrated assessment of chemical mixture effects taking 
into account routes of exposure in different exposure scenarios. We 
support using both monitoring and modelling approaches (EC 2012). 
Following this statement, several efforts have been made to improve risk 
assessment of specific chemical mixtures under the EU regulatory 
framework (Kienzler et al. 2016, Committee et al. 2019, More et al. 
2019, EFSA, 2020a, 2020b). Moreover, a workshop with representatives 
from the EU-funded research projects (EDC-MixRisk, EuroMix, 
HBM4EU, SOLUTIONS, and EU-ToxRisk), Commission services and EU 
agencies concluded that there is a need to identify a range of approaches 
to tackle the complexity of mixture effects (Drakvik et al. 2020). 
Exposure to chemical mixtures (e.g. for substances exhibiting similar 
MoAs) may lead to adverse health effects even at exposures below a 
chemical’s threshold level. Additionally, exposure to multiple chemicals 
significantly above their respective threshold level, toxicokinetics and/ 
or toxicodynamic interactions may occur, resulting in new toxic effects 
usually not observed for single exposures because of potentiation or 
synergism. Nevertheless, such interactions are difficult to predict. These 
assessments should be based on data from measuring and simulating 
relevant mixtures in models and by measuring a wide array of molecular 
biomarkers of target organ toxicity and nonspecific biomarkers of toxic 
response (oxidative stress, DNA damage, etc.) in different body fluids 
(Hernández et al. 2019). 
The use of effect biomarkers in studies of complex exposures could 
help to identify both the active components of the mixtures/combined 
exposure as well as the consequences of specific mixture exposures 
(Silins and Högberg 2011). 
in silico models can also help in evaluating effects from exposures to 
chemical mixtures (Sauer et al. 2020). Whereas the MoAs are not known 
for some chemicals in the mixture, one possibility is to read across, 
which can be used to cluster substances following the concentration 
addition concept. In silico models and read across tools for MoA often 
refer to collections of structural alerts, which can be used to identify 
families of substances with the same MoA. The identification of these 
families should involve multiple perspectives, based not only the 
chemical similarity, but also on the toxicological, toxicokinetics and 
physico-chemical properties. Examples of the available software tools 
for the use of in silico models and read across comprise the OECD QSAR 
Toolbox2, VEGA3, and AMBIT4. Furthermore, other models can be useful 
to assess possible interactions, for instance using a program that predicts 
if a substance inhibits the activity of an enzyme involved in the meta-
bolism of a second substance. 
3.1.4. Examples using bioassays to characterize the combined effect of real- 
world chemical mixtures: Endocrine disrupting chemicals 
One of the main challenges when evaluating the effects of exposure 
biomarkers for endocrine disrupting chemicals (EDCs) is that there are 
many known and unknown compounds in a complex mixture. EDCs are 
important reproductive toxicants. Xenoestrogenicity/Antiandrogenicity 
due to exposure to mixtures have been associated with hormone 
dependent cancers in humans such as breast cancer, cryptorchidea/ 
hypospadias, birth weight and neurodevelopmental disorders (Vilahur 
et al. 2013, Vilahur et al. 2014, Arrebola et al. 2015, Pastor-Barriuso 
et al. 2016). Ex vivo bioassays can evaluate the combined effect of 
complex chemical mixtures in human samples. 
Within the PROTECTED project in random samples originating from 
the Norwegian HUMIS biobank of human milk estrogenic (using ERα- 
CALUX) and anti-androgenic activities (using AR CALUX bioassays) 
have been detected in response to the presence of anthropogenic polar 
EDCs without direct interferences from natural sex hormones (Collet 
et al. 2020). 
Several different occupational exposure profiles have been also 
linked to estrogenic and androgenic activities in blood of men (Brouwers 
et al. 2011). Elevated androgenic levels were found in smokers and 
heavy drinkers and in men occupationally exposed to disinfectants or 
welding/soldering fumes. Occupational exposure to pesticides, disin-
fectants, and exhaust fumes seemed to be associated with increased 
plasma estrogenic levels. 
Leukemia incidence has increased in recent decades among Euro-
pean children, suggesting that early-life environmental exposures play 
an important role in disease development. There is also increasing evi-
dence that some kind of cancer risks are linked with EDCs interfering 
with growth and sexual hormone system. This evidence is supported by 
estrogenic and androgenic activities (ER and AR CALUX) in ~ 750 blood 
samples from mother-child cohorts from five different European coun-
tries within the NewGeneris project. The examples show that with 
existing HTS technics relevant information for health protection can be 
generated (Judson et al. 2018). And endocrine disrupting MoAs that 
may contribute to carcinogen-induced leukemia and require further 
research (Merlo et al. 2014). 
However, one of the challenges using bioassays is that, when the 
composition of the mixture is unknown, its inclusion in risk assessment 
is difficult. Therefore, it is important to isolate specific chemical families 
and test their combined activity. For example, mixtures of PFAS were 
isolated from serum obtained from 702 pregnant women (Bjerregaard- 
2 https://www.oecd.org/chemicalsafety/risk-assessment/oecd-qsar-toolbox. 
htm  
3 https://www.vegahub.eu/  
4 http://ambit.sourceforge.net/ 
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Olesen et al. 2015), and showed that the PFAS mixture exerted a higher 
xeno-estrogenicity, which was associated with reduced fetal growth 
suggesting an estrogenic MoA on this outcome (Bjerregaard-Olesen et al. 
2019). This opens the possibility to evaluate the combined effects of 
chemical families and mixtures in human populations, and efforts are 
needed to integrate this approaches in risk assessment. 
Subsequently, comprehensive characterization of exposures and ef-
fects in an integrated fashion will facilitate inferences for regulatory risk 
assessment (Fan et al. 2019, Jarabek and Hines 2019). 
3.2. Part II. Approaches to handle complexity of effect biomarker utility 
3.2.1. Adverse outcome pathway (AOP) and its role in revealing effect 
biomarkers 
One of the important sources of information for potential biomarkers 
identification and interpretation could be the molecular initiation events 
(MIEs) and key events (KEs), especially those common KEs, described in 
the existing framework of Adverse Outcome Pathways (AOP; OECD, 
2018). Currently, available AOPs can be retrieved from the AOP 
knowledge base (AOP-KB), which was developed under the OECD um-
brella. The AOP-KB is an open-data repository of chemical induced 
toxicity pathways as part of the OECD AOP Development Effort by the 
Extended Advisory Group on Molecular Screening and Toxicogenomics 
(EGMAST). The Adverse Outcome Pathway Knowledge Base (AOP-KB)5 
is the main entry point. It consists of two main modules: the AOP-Wiki6 
and the Effectopedia7. The AOP-Wiki is designed to support formal, 
qualitative AOP development following the guidance provided in the 
OECD Users’ Handbook (OECD, 2018). Qualitative AOP provides a 
scientifically credible basis to link apical hazards of regulatory concern 
to specific pathway perturbation or altered biological processes (often 
measured using in vitro assays). However, for many regulatory purposes 
the exposure data are required (dose, duration, frequency etc.) under 
which an adverse outcome (AO) will be observed. This information is 
captured in Effectopedia, where data on dose- and time-response are 
introduced. This information can be used to derive quantitative 
response-to-response relationships between KEs (quantitative AOPs) 
resulting in an AO. Therefore, regulators seeking mechanistic informa-
tion to support the chemical safety evaluation process can consult the 
AO-KE information. The mechanistic information facilitates the identi-
fication of effect biomarkers that then can be further validated prior to 
their implementation for various regulatory purposes (Sachana 2019). 
Furthermore, reliable effect biomarkers can be interpreted and used 
better, when there is a sufficient understanding of the AOP or mode of 
action (MoA) of the chemical, and a causal relationship of biological 
events linking the marker and the AO. This can be achieved by devel-
oping AOP or even better AOP networks, for a specific AO/disease 
through sharing of KEs and key event relationships (KERs). However, 
the molecular initiating event (MIE) in an AOP can be initiated by a 
variety of chemicals, while a related MoA can be specific for a chemical. 
Therefore, from the AOP a MoA can be developed by including 
chemical-specific information and a prediction of the relationship be-
tween the chemical concentrations at the site of the MIE, causing the 
MIE perturbation, which would then trigger a cascade of key events 
resulting in AO. AOP describes a sequence of key events (KEs) beginning 
with the initial interaction of a chemical with a molecule in a target cell 
or tissue (MIE) progressing through causally linked KEs at different 
biological organization (cell, tissue, organ, organism), resulting in an AO 
(Bal-Price et al. 2017, Corton 2019). KEs must be empirically observable 
and should be reproducibly and quantitatively measurable using 
different test systems. Early KEs (molecular or cellular events) can serve 
as a basis to develop mechanistically based, reliable and predictive effect 
biomarkers for adverse outcome/disease, that are easily measured using 
in vitro assays. AOPs developed according to the OECD template should 
be submitted to the OECD AOP -Wiki where they are publicly available 
and can serve as a reliable source of information when identifying po-
tential effect biomarkers. Each individual AOP should be considered as a 
building block within a larger AOP network that represents more 
comprehensively the complexity of biological processes involved in an 
adverse outcome (Bal-Price et al. 2017). Moreover, MIE of a single AOP 
is likely to be triggered by a limited number of compounds and probably 
belonging to the same class. Therefore, a development of an AOP 
network by assembling individual AOPs, interconnected through com-
mon KEs is a more reliable approach as shown in the case of neurotox-
icity (Spinu et al. 2019). 
The identified CKEs in the AOP network can serve as reliable anchors 
for identification of effect biomarker in in vitro assays for single chem-
icals or mixtures. A threshold value defined for MIEs (or KEs) can 
directly inform risk assessment for regulatory purposes. In environ-
mental risk assessments the terminology effect-based trigger values is 
used (Escher et al. 2018, Brion et al. 2019), but for occupational as-
sessments the terminology Occupational Biomonitoring Effect Level 
(OBEL) was proposed this year in the Occupational Biomonitoring ac-
tivity of OECD Working Parties on Exposure and Hazard Assessments 
(WPEA/WPHA) (2nd Webinar on the 3rd of April 2020). An easy 
translation of identified mixture effects by existing biomonitoring 
knowledge can be envisaged. Occupational Biomonitoring Levels (OBL) 
are linked to adverse and accepted Point of Departures (PoD) in risk 
assessments. Therefore, if a mixture response of an effect biomarker 
exceeds an OBL as an equivalent concentration (e.g. lead (Pb) can be 
used as trigger equivalence substance for many neurotoxic effects), an 
identification for an adverse risk potential is given and can trigger 
further steps. This approach needs to be further discussed and developed 
to bridge exposure and effect biomarkers in the future (see chapter 3.3). 
Recently such an approach was used for the evaluation of develop-
mental neurotoxicity (DNT) effects induced by a combined exposure to 
mixtures of different classes of chemicals (Pistollato et al. 2020). Effect 
biomarkers in in vitro assays were used to evaluate synaptogenesis, 
neurite outgrowth, and brain derived neurotrophic factor (BDNF) pro-
tein levels. BDNF levels were identified as CKEs in the AOP network 
relevant to impairment of learning and memory in children (recently the 
most prevalent AO) (see Fig. 1 in Pistollato et al.) (Pistollato et al. 2020). 
Scientific validation of 16 DNT in vitro assays and their readiness for 
diverse regulatory applications have recently been evaluated. Thirteen 
semi-quantitative criteria were used for this evaluation referring to the 
characterization of diverse test systems, exposure schemes, main 
measured endpoints, cytotoxicity, test methods controls, data evalua-
tion, reproducibility, test benchmarks (sensitivity, specificity and 
acceptance criteria), prediction model, applicability domains and defi-
nition of a hit (Bal-Price et al. 2018). Inclusion of this battery of in vitro 
test methods in the OECD Guidance Document for in vitro DNT testing is 
planned. It is currently under development in collaboration with EFSA 
and US EPA (Sachana et al. 2019). 
Sensitivity of the proposed in vitro assays is evaluated by comparing 
neurotoxic effects that are observed at the concentrations below 
acceptable population blood levels. For example in occupationally 
exposed adults, subtle or nonspecific neurocognitive effects have been 
reported at blood lead levels as low as 20–30 µg/dL (Mantere et al. 1984, 
Schwartz et al. 2001), with overt encephalopathy, seizures, and pe-
ripheral neuropathy generally occurring at much higher levels (e.g., 
higher than 100–200 µg/dL) (CDC, 2017). Lead is also an important 
neurodevelopmental toxicant since it crosses the human placenta and 
accumulates in fetal tissue during gestation (Gundacker and 
Hengstschläger 2012). Although, no blood lead level for children is 
considered safe, most governmental agencies, including the US Envi-
ronmental Protection Agency and Centers for Disease Control and Pre-
vention (2012), have concluded that there is sufficient evidence for 
adverse health effects in children and adults at blood lead level below 5 
5 https://aopkb.oecd.org/index.html  
6 https://aopwiki.org/  
7 https://www.effectopedia.org/ 
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μg/dL. This level was derived from the upper 2.5% distribution of blood 
lead levels among U.S. children ages 1–5 years. Indeed, several research 
groups observed impaired cognitive functions at levels as low as 5 μg/dL 
(Chiodo et al. 2007, Bellinger 2008, Jusko et al. 2008). Furthermore, 
sensitive in vitro effect biomarkers e.g., synaptogenesis quantification, 
can identify the toxic effects from lead exposures as low as 0.2 µg/dL 
(Pistollato et al. 2020). This demonstrates that the in vitro assays have 
sufficient sensitivity to identify neurotoxic effects. 
3.2.2. Application of physiologically based kinetic modelling for exploring 
effect biomarkers of mixtures 
Physiologically Based Kinetic and dynamic (PBK/D) models can 
assist in evaluating the appropriateness of effect biomarkers utility. 
PBK/D models are built using biologically relevant compartments rep-
resenting organs of the body interlinked by blood circulation. The 
models are driven by mass-balance ordinary differential equations 
(ODEs) to describe the ADME processes of a chemical as a function of the 
physiochemical (tissue:blood partition coefficient), biochemical (meta-
bolic rate constant, like Vmax and Km), and physiological (body weight 
and tissue volume) characteristics with link to dynamic endpoints. In-
ternal concentrations of chemicals and relevant metabolites and/or 
biological changes can be estimated with PBK/D models which are not 
feasible in humans (Phillips et al. 2014). When co-exposure to multiple 
chemicals is considered, changes in the rates of ADME processes should 
be taken into account. For instance, the distribution rate may differ due 
to competitive binding sites to protein, reduction of metabolic rate 
(inhibition) may be the result of two or more chemicals competing for 
the same enzyme (Tan et al. 2011). As reported in Tan et al. 2011 a 
mechanistic model for chemical mixtures should take into account three 
major elements: (1) The interaction among individual chemicals in the 
mixture at the level of kinetics and dynamics; (2) Quantitative de-
scriptions of both temporal (i.e., concurrent or sequential exposures) 
and dose relationships among individual chemicals; and (3) Each 
chemical’s mode of action. PBK/D models for single chemical or a 
mixture of chemicals can provide insight into the selection of biomarkers 
of effects to strengthen the correlation between exposure and endpoint/ 
adverse outcome. Table S2 in the Supplementary Material expands the 
work published by Desalegn et al. (2019), who identified 35 types of 
PBK/D models developed in the last three decades for mixtures. In 
addition, the pathways of effect, effect biomarkers and endpoints for 
several classes of chemicals and with different complexity of mixtures 
were mapped. Among these studies, PBK/D models were built to simu-
late the kinetics of the alkenylbenzene class (Estragole, Safrole, Meth-
yleugenol), which are known to be hepatocarcinogenic in rodent species 
(Desalegn et al. 2019). Not only the kinetics were investigated, but also a 
translation of results into the likelihood of formation of DNA adducts 
(Paini et al. 2010, Martati et al. 2014). By expanding the PBK model to 
PBD model to predict in vivo DNA adduct formation in liver, it was 
shown how an early effect biomarker, can provide a step closer to the 
ultimate toxic effect (genotoxicity) (Paini et al. 2010). Other examples of 
biomarkers and PBK/D models for VOCs, Pesticides, Aldehydes and PCB 
are summarized in the Supplementary Material Table S2. These studies 
are also described in Tan et al. (2011) showing the potential of using 
effect biomarkers with PBK/D models. Overall, the proper use of PBK 
models can help in understanding the uncertainties that arise from 
biokinetic interactions and disposition of chemical mixtures and to 
identify data gaps to derive health-based guidance values (RfD and/or 
ADI). These models can be developed to describe the MoA and tissue 
responses of a chemical, but also incorporate information on the human 
inter-individual variability and incorporate complex elements (like fetus 
compartment). By linking the kinetics to the associated dynamic health 
risks, the exposures to complex chemical mixtures can be assessed due to 
identification and quantification of biomarkers of effect. PBK/D models 
can enhance the interpretation of effect biomarkers by providing insight 
into quantitatively connecting external exposure to the internal con-
centration at the organ site linked to known key events (Phillips et al. 
2014). 
PBK/D models have several advantages but also some limitations. To 
be able to interpret and simulate an effect biomarker the model must 
have a higher degree of complexity including, for instance, metabolism 
or including other dynamic processes underling the chemical MoA. PBK/ 
D models have the potential to extrapolate outside the range of con-
straining data but within quantifiable limits of uncertainty for complex 
mixtures (Jasper et al., 2016). Here expert judgment come in accounting 
for between model simplicity and complexity, and biological plausibil-
ity. PBK/D models can also help in understanding how specific an effect 
biomarker is to a specific chemical within a mixture, like a “specific 
fingerprint”. Finally, it is known that the kinetic interactions due to 
mixture exposures can significantly complicate the interpretation of 
HBM data. However, PBK/D models can help to interpret HBM, 
providing the understanding of chemical exposures and biomarkers of 
effects in human populations. In addition, application of the PBK/D 
models accounts for ADME processes and helps in establishing the de-
gree of correlation between the biomarker and the metric of interest and, 
finally, they can facilitate the discovery of new biomarkers (Phillips 
et al. 2014). 
3.3. Part III. Use of effect biomarkers in occupational biomonitoring 
The OECD Occupational Biomonitoring subtask effect biomarkers is 
an Ad hoc expert group proposed for OECD WPEA and OECD WPHA in 
April 2019 and launched in September 2019 as a joint proposal from 
biomonitoring experts from four countries. This group now has support 
from more than 60 experts representing 40 different institutes and aims 
to provide a biomonitoring guidance for effect biomarkers. This group 
has produced a set of priority mode of actions, recommendations of 
usable effect biomarkers, and a suitability checklist for characterizing 
effect biomarkers. The following sections describe the status, pre-
liminary conclusions, and knowledge collected by this group. The cur-
rent use of biomarkers was intensively discussed within ISES Europe 
activities and have been described in a recent publication (Viegas et al., 
2020). 
3.3.1. Rationale for implementing the use of effect biomarkers in 
occupational biomonitoring 
The knowledge regarding co-exposures to chemicals is quite limited 
for many work situations. This is mainly because it is difficult to identify 
all the compounds and their fluctuations during the wide diversity of job 
tasks performed during a workday or production period. In addition, 
little information is available regarding the effectiveness of the risk 
management measures (RMM) in place, particularly for personal pro-
tective equipment. 
Numerous studies have shown a significant association between 
occupational exposures to chemicals and various diseases including 
chronic diseases such as cancer (Prüss-Ustün et al. 2011, Purdue et al. 
2015). Despite this knowledge, only very few chemicals at work are 
measured which is often due to cost constraints and analytical limita-
tions. The economic cost of cancer has been estimated to 396′000 Euro 
per case in an ECHA study (Ščasný and Zvěřinová 2014). For compari-
son, the value of a statistical life was estimated at 6.2 million Swiss 
francs or 5.5 million Euros (OECD 2012). Moreover, occupational dis-
eases not only reduce life expectancy but can also lower productivity 
because, besides mortality, morbidity is also responsible for high eco-
nomic costs to society. An overview of economic costs and effects of 
policies aiming at reducing work-related diseases and injuries can be 
found in Appendix B, Fig. B1. 
Workers are exposed to a large number of chemicals, products and 
formulations as well as physical and biological agents; however, only a 
few of these are characterized in terms of health risks. For example, an 
exposure scenario in the REACH regulation estimating the probability 
and intensity of exposure for a relevant work activity is only required if 
the chemical is put on the market at 10 tons per year and carries a hazard 
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classification (ECHA. 2016). The toxicological data for many chemicals 
is insufficient or inconclusive for a hazard classification. The law re-
quires ECHA to check at least 5% of the registration dossiers for 
compliance. In a majority of the dossiers that ECHA checks for compli-
ance, important safety information on chemicals are omitted. ECHA 
then requests this information to complete the registration dossier. 
Moreover, some industrial processes can change often and workers need 
to adapt to these changing working conditions. These changes will likely 
result in different occupational exposure scenarios implying different 
chemical substances at variable levels and durations. Few regulator-
ydemanded exposure scenarios can only try to reflect a part of this ever- 
changing reality. Consequently, there exists a large knowledge gap and 
uncertainty in the current substance-based risk assessment EU approach, 
where no options to change it midterm exists. To address these chal-
lenges in the future, we recommend using suitable effect biomarkers. 
Integrating effect biomarkers into HBM programs as occupational risk 
assessment and management tools, can directly quantify the effects of 
the occupational exposure from single chemicals and chemical mixtures. 
These HBM programs have an important role in occupational health 
interventions since it provides information about the group of workers 
with higher risk that should be targeted for RMM. We provide here ex-
amples of successfully developed biomarkers, their application, and 
explore their potential use in occupational risk management. 
3.3.2. Setting the priority mode of actions (MoA) and endpoints to be 
addressed 
The OECD occupational biomonitoring subtask effect biomarker 
have prioritized eight relevant MoAs that should be considered when 
assessing occupational health. These MoAs are listed in random order in 
Table2 taking into account existing (CMR, ED) and needed classifica-
tions to cover important safety gaps for workers. 
3.3.3. Recommendation of effect biomarkers and promising assays by 
experts 
The experts in the OECD occupational biomonitoring subtask effect 
biomarker were asked: Which effect biomarkers should be used? Which 
are the promising assays to develop future effect biomarkers? This list of 
potential suitable effect biomarker was discussed, refined and concluded 
in several meetings and is provided in Table 3. 
3.3.4. Examples using effect biomarkers for detection of genotoxic and 
carcinogenic substances 
One of the main challenges of exposure biomarkers is that they are 
limited to assessable and analytically detectable compounds. Hex-
avalent chromium (Cr (VI)) is and remains an important occupational 
carcinogen. Exposures to Cr (VI) cause lung cancer in humans. The main 
limitation of urinary chromium detection is that it is not specific for Cr 
(VI) since it measures exposure to both Cr(III) and Cr(VI). Also, the 
lowest biological limit value (BLV) given for Cr(VI) (2.5 μg/L in France), 
which is close to background urinary Cr levels in populations with no 
known occupational exposure (e.g.in France 95th percentile in general 
population is 0.65 μg/L (ANSES 2017)). These circumstances illustrate 
the need to develop biomarkers specifically indicating Cr(VI) or effect 
biomarkers assessing overall genotoxic and carcinogenic risk, which are 
associated with exposures to the mixture. In the HBM4EU project, 
around 400 samples from workers exposed to chromium will be 
collected from eight European countries (Belgium, Finland, France, 
Italy, Poland, Portugal, the Netherlands and the United Kingdom (UK)). 
This study have been described in Santonen et al. (2019). The study 
compares exposure biomarkers with some selected effect biomarker for 
genotoxicity with micronuclei frequency, oxidative stress, and telomere 
length as well as an epigenetic biomarker. This study intends to the 
comparison of several markers of exposure and effect in a variety of 
exposure scenarios (Santonen et al. 2019). The results of the study will 
be reported within the reporting policy of the HBM4EU project, and a 
general report will be publicly accessible via the project website8. 
Additionally, a recent systematic review and meta-analysis of most 
recent literature on occupational exposure to styrene using the 
cytokinesis-block micronucleus (CBMN) assay identified a 34% overall 
increase of genomic instability and DNA damage in exposed workers as 
compared to unexposed controls, regardless of gender, age or smoking 
status. This result revealed convincing evidence linking exposure to 
styrene with micronuclei frequency and supports the use of the CBMN 
assay in monitoring genetic risk in workers (Costa et al. 2016). 
3.3.5. Checklist to select appropriate effect biomarkers in occupational 
studies 
A suitability checklist to characterize the recommended effect bio-
markers was developed by the OECD biomonitoring effect biomarker 
subgroup. In principle, all the relevant MoAs (Table 2) can be covered by 
at least one effect biomarker associated with validated methods (see 
Table 3 with OECD and DIN EN ISO guidelines or standards). However, 
they are not necessarily suitable occupational effect biomarkers. Only 
some of these biomarkers are recommended (see Table 3) for further 
characterization. Neurotoxicity and respiratory toxicity are only 
included in the German occupational risk assessment. Effect biomarkers 
for reproduction and developmental toxicity are not easily feasible. One 
reason is that these effects can mainly be detected with long-term 
exposure experiments that can detect effect during a sensitive life 
stage. For effect biomarkers to be a suitable tool in occupational health 
risk management, they need to be reliable, robust, and provide an un-
derstanding of exposure and effect in the human body. Effect biomarkers 
need to be characterized in both internal and external validation pro-
cesses. Validated test guidelines should be preferred, such as OECD test 
guidance or DIN EN ISO standard, to ensure analytical accuracy, 
reproducibility, and reliability. The suitability of these recommended 
biomarkers will be rated by effect biomarker experts, effect biomarker 
developers and applicants using a set of 13 questions (see Supplemen-
tary, Table S3) evaluated by a scoring system (HBM4EU et al., 2017). 
This should provide a more detailed understanding of the suitability of 
each of these biomarkers concerning validation, relevance, sensitivity, 
specificity, cost-efficiency, and robustness. The results of this survey are 
expected later this year. 
Table 2 
Proposed priority mode of actions /endpoints to be addressed by occupational 
biomonitoring.  
No Mode of actions /endpoints Abbreviation Available methods as 
OECD guideline, DIN EN 
ISO standards or others 
1 Carcinogenicity (including 
cancer biomarkers for 





2 Mutagenicity M yes 
3 Reproduction toxicity R yes 
4 Endocrine disruption ED yes 




6 Developmental Neurotoxicity DNT OECD GD on in vitro DNT 
assays is under 
development 
7 Developmental Toxicity DT yes 
8 Respiratory toxicity 
(including methemoglobin 
binding) 
ResT yes  
8 https://www.hbm4eu.eu/ 
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Table 3 
Potential suitable effect biomarkers to be characterized for occupational use or already applied in other contexts.  
No Covered MoA or endpoint Name of the assay or effect biomarker Biomarker 
categorization 
Measured endpoint 
1a C including genotox Mammalian Erythrocyte Micronucleus 
Test 
Peripheral blood lymphocyte 
micronucleus test 
ex vivo induction rate of micronuclei 
1b C including genotox Buccal micronucleus assay ex vivo induction rate of micronuclei in buccal cells 
Micronuclei frequencies epithelial buccal cells 
1c C including genotox Cytokinesis-block micronucleus assay 
(CBMN-Assay) 
ex vivo induction rate of micronuclei in peripheral blood 
lymphocytes 
1d C including genotox Peripheral blood lymphocyte 
micronucleus test and Buccal mucosa 
micronucleus test 
ex vivo Micronuclei frequencies in lymphocytes and in 
epithelial buccal cells 
1e Oxidative stress level indicative for C and 
genotox 
reduced/oxidized glutathione (GSH/ 
GSSG) ratio 
ex vivo increase or decrease of the GSH/GSSG ratio 
2a M The Ames Test/Bacterial Reverse 
Mutation Test 
in vitro measuring reverse mutation in bacterial cells 
3 R Reproductive Hormones - testosterone, 
estradiol, Luteinizing hormone, Follicle 
Stimulating Hormone 
ex vivo measuring levels in serum 




ED- AR receptor activation 
ED- TR receptor activation 
AR CALUX 
TR CALUX, anti-TR CALUX, TTR-TR 
CALUX, TTR-FITC assay, TPO assay 
in vitro 
in vitro 
measuring the receptor activation of the human 
androgen receptor 
measuring the receptor activation of the human 
thyroid receptor 
4d ED-steroidogenesis modulation H295-R-steroidogenesis modulation 
assay 
in vitro measuring steroidgenesis modulation 
5a inhibition of acetyl-choline-esterase acetylcholine-esterase-inhibition assay biochemical/ 
biological 
Measuring inhibition of acetyl-choline- esterase 




Neurofilament-light chain (NF-L) in serum 




Neurofilament light chain (NfL), neurofilament 
medium chain (NfM), neurofilament heavy chain 




Evaluation of key neurodevelopmental processes 
as Brain Derived Neurotrophic Factor (BDNF) 
(indicative of neuronal survival, development 
and synaptic plasticity) 
Neurite outgrowth, synaptogenesis, glial 
proliferation, migration and neuronal 
electrical activity brain Derived 
Neurotrophic Factor (BDNF) 





in vitro assays 
in vitro 
and/or 
in blood sample 
Measurements of length, number of neurites and 
branching points per neuron; expression for pre- 
and postsynaptic protein (e.g. co-localization of 
synaptophysin and PSD95); number of diverse 
neuronal and glial subtypes; measurements of 
cell migration distance; 
recording of neuronal electrical activity 
(spontaneous or evoked) using microelectrode 
array (MEA) 
Measurements of BDNF at protein and mRNA 
levels 
6b DNT Thyroid stimulating hormone (TSH), 
triiodothyronine (T3), thyroxine (T4) 
biochemical/ 
biological 
Levels in serum during pregnancy 
7a The murine embryonic stem cell test (EST) – to 
assessembryo-toxicity (teratogenicity) potential 
of chemicals* 
Sarcomeric myosin heavy chain and 
alpha-actinin proteins 
in vitro Quantitative expression of sarcomeric myosin 
heavy chain and alpha-actinin proteins in 
beating cardiomyocyte’s as well as counting of 
contracting cardiomyocyte agglomerates. The 
morphological analysis of beating 
cardiomyocytes in embryoid body outgrowths 
compared to cytotoxic effects on murine ES cells 
and differentiated 3 T3 fibroblasts. 
7b Male-mediated developmental toxicity and 
mutagenicity* 
dominant lethal and specific locus 
mutation tests: in vivo; DNA 
methylation: in vitro 
Different biomarkers 
in battery 
Battery of tests to identify germ cell mutations, 
such as dominant lethal and specific locus 
mutation tests, epigenetics (DNA methylation e. 
g. acrylamide, lead) 
8a Methemoglobin respiratory toxicity Methemoglobin binding assay ex vivo / biochemical measurement of building of methemoglobin 
which is functional inactive  
* Will be not characterized further due to expected sensitivity coverage under DNT. 
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3.3.6. A tiered- approach for interpretation of effect biomarker responses 
A tiered approach is proposed for using effect biomarkers to indicate 
exposure and health risks. 
- Tier I: relevant MoAs/endpoint is or could be activated due to sig-
nificant elevated effect biomarker levels in the exposed population 
compared to the general population level (baseline) or other evi-
dence that can lead to adverse risks (see classifications in Table 2) 
→ need to determine a provisional Occupational Biomonitoring Ef-
fect level (OBEL) 
- Tier II: exceedance of a provisional Occupational Biomonitoring Ef-
fect level (OBEL)  
→ Prioritization and improvement of Risk Management Measures 
(RMMs), further exposure assessments  
- Tier III: exceedance of a refined OBEL  
→ immediate RMM and health surveillance 
To ensure that an effect biomarker can be used in an occupational 
health context, the response of the effect biomarker needs to be assessed 
and population or similar exposure groups specific cut-offs developed. 
The workplace response of the effect biomarker can be compared with 
the known responses in the general population. If there are no significant 
differences, occupational exposures can be excluded with a high prob-
ability. In case the effect biomarker response exceeds significantly the 
population level it is likely that the RMMs are insufficient or another 
unexpected exposure due to a change in the working conditions 
occurred. This result can trigger a derivation of a provisional 
Occupational Biomonitoring Effect level (OBEL) and later on improve-
ments in the RMMs or further exposure assessments. This should be 
followed by the derivation of a refined health-based OBEL, which should 
consider the AOP knowledge to ensure that the workers are sufficiently 
protected. A procedure on how to conduct such a derivation needs to be 
elaborated, and preferably, within the framework of the ongoing OECD 
activity. 
Challenges on data communication and report can be surpassed by 
applying the Similar Exposure Group (SEG) approach, fully described in 
the European norm EN 689/2020 2020 (Workplace Exposur-
e—Measurement of Exposure by Inhalation to Chemical Agents—-
Strategy for Testing Compliance with Occupational Exposure Limit 
Values). Additionally, the format developed by ECHA for exposure data 
reporting, with some adaptations, can also help reporting biomarkers of 
effect data9. An update proposal for the reporting of effect biomarker 
results is intended within the OECD activity. 
3.3.7. Need of health-related effect-based trigger values for selected suitable 
effect biomarker 
Exposure can be identified easily if the variability of the effect 
biomarker in exposed and unexposed (background) conditions are 
known. It becomes more challenging to assess health risks, but this is 
where effect biomarkers can be used. As a simple rule of thumb, the 
response of most effect biomarkers can be translated into equivalent 
concentration of a MoA specific reference substance. This equivalent 
concentration expresses the mixture effect in terms of an analytical 
comparable value (see Table 4). 
In an optimal case, a valid biomonitoring exposure limit exist for the 
reference equivalent substance and can be compared directly. For 
setting provisional effect-based trigger values, an already existing and 
accepted Occupational Exposure Level can serve as the indicator for 
risks associated with exposure to chemical mixtures. Equivalent con-
centrations above an exposure limit value can be used to identify un-
acceptable health risks and trigger a follow up step. Therefore, for every 
relevant MoA, suitable reference substances should be provided, pref-
erably with existing or easy to derive biomonitoring exposure limits. 
4. Conclusions, outlook and identified needs 
Effect biomarkers assist in elucidating the causal relationship be-
tween exposures and health outcomes in the general and occupational 
population. These type of biomarkers can serve as a powerful bio-
monitoring tool for assessing exposures to known and unknown chem-
ical mixtures, interpreting exposure biomarker measurements, and 
bridging the exposure-health effects relationship gap in risk assessment. 
Despite such advantages, effect biomarkers are only marginally used in 
biomonitoring of human populations. This might be explained by the 
absence of health-based biological limit or guidance values in the gen-
eral and specific populations (e.g., man vs. women, adult vs. children) as 
well as the absence of general guidance on how to use effect biomarkers 
in risk assessment frameworks. Additionally, effect biomarkers are 
required to be sensitive, specific, biologically relevant, feasible, prac-
tical (e.g. in terms of analytical complexity), and inexpensive for use in 
epidemiological, experimental, and mechanistic studies in relation to a 
given chemical compound of interest (Baken et al. 2019). The use of 
effect biomarkers in large studies depend also on the availability of high- 
quality, validated, high-throughput analytical methods. Such robust 
methods ensure that the biomarker data obtained are accurate and 
precise through careful quality control of all steps ranging from sample 
collection to analytical evaluation. 
We showed with the AOP concept that effect biomarker can serve as 
Table 4 
Preliminary list of a suitable reference compounds which can serve for sensi-
tivity comparisons and as provisional Occupational Biomonitoring Effect Levels.  
No Proposed priority 
mode of actions 




















genotoxicity and H202 for 
oxidative stress 
Other substance or 
derivation need for a 
provisional OBEL 
2 Mutagenicity 4-nitro- 
ophenylenediamine or 2- 
nitrofluorene 
Other substance or 
derivation need for a 
provisional OBEL 
3 Reproduction toxicity BPA or DEHP Other substance or 
derivation need for a 
provisional OBEL 
4 Endocrine disruption 17-β-estradiol for 
estrogenicity and 2- 
dihydrotestosteron for 
androgenicity 
Other substance or 






lead or Chlorpyriphos BLV-ECHA/RAC =
150 microgramm/L 
in blood or BGW, 

















Carbon monoxide BGW, TRGS 903 CO- 
Hb: 5% blood  
9 available here: https://echa.europa.eu/documents/10162/22979809/tmpl_ 
reporting_occupational_exp_data_du_en.xlsx/84ef3203-4294-75c8-3b79-9c0 
24abc2bcd). 
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an early warning system in risk assessment. Further, identification of 
effect biomarkers and their mechanistic pathways following the AOP 
framework can definitively help to prioritize the implementation of 
related sets of effect biomarkers in a more structured way, as well as 
improve the interpretation of biomarker data. Given that several 
chemical families can influence an AOP, effect biomarkers integrate the 
convergent effects of chemical mixtures on a particular AO. We conclude 
that regulatory agencies can use AOPs to derive effect based trigger 
values to address adverse risk levels from chemical exposures, and then 
identify MoAs that relate exposure to response to set these limit values. 
Simulation tools such as PBK/D modeling can help in this regard. 
Several effect biomarkers are validated for relevant MoAs and offer a 
direct assessment of overall health risks associated with exposure to 
chemicals, their transformation products and chemical mixtures. An 
important step forward is a list of relevant MoAs generated by the reg-
ulatory agencies that can be implemented in an EU-wide human bio-
monitoring strategy. The EU HBM4EU project is currently comparing 
exposure biomarkers for chromium and some selected effect biomarkers 
for the general population and workers, but no regulatory use in pop-
ulation monitoring as of yet. The OECD Occupational Biomonitoring 
activity of the Working Parties of Hazard and Exposure Assessment has 
prioritized eight relevant MoAs. They recommend characterizing 20 
more suitable effect biomarkers. We propose to use the existing AOP 
knowledge for derivation of cross-regulatory usable effect-based trigger 
values to be able to address exposures to known and unknown chemical 
mixtures. As a starting point, MoA specific exposure biomarkers can be 
used for further refinements. Inter-regulatory agency collaborations 
would not only reduce the fragmentation observed in different regula-
tions, but also stimulate a harmonized use of effect biomarkers and 
development of new and the use of already established effect bio-
markers. To this end, ISES Europe and OECD Occupational Bio-
monitoring working groups suggest developing a list of suitable effect 
biomarkers for regulatory use. Furthermore, a considerable amount of 
consistent data is necessary to quantitatively link results from different 
studies. Developing reporting standards would ensure reliability, 
reproducibility and efficiency of data collection, as well as transparency 
when interpreting findings, and relevance for evaluations, ultimately 
increasing their utility for informing regulatory risk assessment. 
Therefore, development of a reliable effect biomarkers’ database, linked 
to exposure and susceptibility biomarkers, although challenging, is 
necessary for the best use of available data. The overarching direction is 
to advance the use of effect biomarkers in exposure science and imple-
ment these in ISES Europe’s general HBM strategy roadmap. The link of 
existing suitable effect biomarker with future effect-based trigger values 
will lead to an improved and systematical use of effect biomarker. 
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Appendix A 
In silico Models simulating environmental exposures and/or human 
exposures exist and can estimate internal dose in an organism. Most of 
the efforts have been directed to model the internal dose of pharma-
ceuticals. There are also software programs applicable to animals, which 
are relevant for human health, when the animal or its products are used 
as food for humans. 
Regarding the possible use of in silico tools for the adverse effects, 
there are hundreds of models available. Some platforms are commercial 
and require a payment, while others are freely available. Examples of 
freely available platforms are the OECD QSAR Toolbox10, EPISuite11, 
TEST12, VEGA13, the Danish QSAR Database14, Toxtree15, QSAR DB16, 
and OCHEM17. 
The possibility to estimate exposure levels, and also effect biomarker 
levels for a large number of substances can facilitate the assessment of 
the overall scenarios to be investigated. There are several advantages 
offered by in silico models. They are fast, and the predictions can be 
obtained immediately. They can process a large number of substances; 
for instance, within the PROSIL projects18 6 million compounds have 
been processed for ten endpoints. As already mentioned, there are 
hundreds of tools which are free and easily accessible. They do not 
generate waste, do not use animals, chemical substances, solvents, and 
can be interrogated without the physical substance to be assessed, thus 
can be used also for hypothetical substances, before their preparation. 
Another advantage is that the results from multiple tools can be 
easily wrapped, even though this may require some work. The EC 
project VERMEER19 is producing a single platform integrating models 
for exposure and hazard, to facilitate the user. 
Appendix B 







13 https://www.vegahub.eu/  
14 http://qsar.food.dtu.dk/  
15 http://toxtree.sourceforge.net/  
16 https://qsardb.org/  
17 https://ochem.eu/home/show.do  
18 http://www.life-prosil.eu/  
19 https://www.life-vermeer.eu/ 
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Appendix C. Supplementary data 
Supplementary data to this article can be found online at https://doi. 
org/10.1016/j.envint.2020.106257. 
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